VEEV
Veeva Systems
$230.28
▲ 5.7%Updated Aug 7, 11:30 AM ET
VEEV at a glance — five pillars scored 0–100 from real filed financials.
Overall: Favorable · 69/100. A wider, greener shape means more pillars look healthy. Dividends scores 0 when a company pays none — that is a choice, not a flaw.
▼ Down 45.5% over the last 12 months
Market Cap
$30.68B
P/E
38.97x
Forward P/E (est.)
32.5x
ROE
13.4%
Revenue Growth
16.3%
EPS Growth
19.9%
Profit Margin
28.4%
FCF Yield
2.1%
Debt / Equity
0x
ROIC
10.0%
Interest Coverage
—
Current Ratio
4.74x
Dividend Yield
—
Implied Growth (rev. DCF)
—
Rating Score
69/100
Veeva Systems (VEEV) is a large-cap company in the Health Care Technology industry, part of the Health Care sector of the S&P 500, with a market value around $30.68B.
In its latest reported year it generated about $3.20B in revenue and $908.91M in net profit.
Our model rates VEEV Favorable (69/100) on growth, profitability, financial health, and valuation. The summary below is built from its filed financials and current ratios and refreshes automatically.
Evidence of durable competitive advantage in the filed financials (10 years of history).
The filed history looks like a business competitors struggle to attack: high and steady margins, revenue that grows through cycles, and strong returns on capital.
73.8% average over the last 3 years
±2.0 pts around 72.0% across 10 years
grew in 9 of the last 9 year-over-year periods
positive in 10 of 10 years
10.0% latest fiscal year
A moat can't be proven by numbers alone — this scores the evidence a durable advantage leaves behind (pricing power, consistency, returns on capital), computed the same way for every stock. Pair it with the business overview before concluding anything.
Technical analysis reads price and volume to judge momentum and timing. It complements the fundamentals above — it does not replace them. Here is what VEEV's chart says today, with each tool explained.
Trend — moving averages. A moving average is the average closing price over a window, which smooths out daily noise. VEEV trades near $230.28, above its 50-day average ($165.49) and 200-day average ($213.36). Price above both averages, with the shorter one above the longer, is the textbook definition of an uptrend — momentum favours buyers.
Momentum — RSI. The Relative Strength Index runs 0–100 and measures how strong recent gains are versus losses. Above 70 is "overbought", below 30 "oversold". At 75 it is overbought — the recent rally is stretched and can cool off.
MACD. MACD compares two moving averages to flag shifts in momentum. Its histogram is currently positive — short-term momentum is improving.
Volatility — ATR. Average True Range is the typical daily move. VEEV's is $7.35 (~3.2% of price), so swings of about that size each day are normal — handy for setting a stop that isn't too tight.
Support & resistance. Over the last month VEEV found buyers near $150.39 (support) and sellers near $192.90 (resistance); its 52-week range is $148.05–$310.50. A decisive break beyond either edge often marks the next move.
Volume. The latest session traded 0.9× the 20-day average — about normal. Rising volume on up-days suggests real buying; on down-days, real selling.
Educational information to help you read a chart — not a recommendation or a forecast. It updates daily as the price and indicators change.
4Y CAGR
14.6%
Revenue moved from $550.54M in 2017 to $3.20B in 2026, a 21.6% compound annual growth rate. The most recent year grew a strong 16.3% year over year. Consistent top-line growth is one sign of healthy demand.
Gross Margin
75.5%
Operating Margin
28.7%
Net Margin
28.4%
ROE
13.4%
Veeva Systems keeps about 28.4% of each sales dollar as net profit, with a 75.5% gross margin and 28.7% operating margin. Return on equity is 13.4% and return on invested capital about 10.0%. Margins this wide usually signal pricing power or a cost advantage.
Total Debt
—
Net Debt
—
Net Debt / EBITDA
—
Debt / Equity
0x
Leverage: debt-to-equity is 0.0x, with a current ratio of 4.7x. That is a conservative balance sheet — a cushion in downturns.
Operating CF
$1.42B
Free Cash Flow
$1.42B
FCF Margin
44.3%
In the latest year Veeva Systems produced about $1.42B of operating cash flow and $1.42B of free cash flow after capital spending. That is a free-cash-flow yield of about 2.1% on today's price. Cash flow is what ultimately pays shareholders, so it is worth tracking over time.
P/E
38.97x
P/S
8.15x
P/B
6.53x
EV / EBITDA
—
VEEV trades at 39.0x trailing earnings (about 32.5x on estimated forward earnings), 8.1x sales, and 6.5x book value. That is a premium multiple that needs growth to justify it.
Where VEEV sits versus its Health Care sector peers in the S&P 500.
Bands show the middle half (25th–75th percentile) of the 83 Health Care companies in the S&P 500 — the peer-relative anchor professional comps analysis uses. Context only — not investment advice.
How VEEV stacks up against its Health Care peers — valuation, profitability, and growth versus the sector median.
In the Health Care sector (324 S&P 500 companies), VEEV ranks #12 of 324 by our overall rating. It trades at a premium versus the sector on earnings (39x P/E vs. 27.3x median) with a lower return on equity (13.4% vs. 14.1%) and faster revenue growth (16.3% vs. 7.6%).
P/E vs sector
39x
median 27.3x
ROE vs sector
13.4%
median 14.1%
Growth vs sector
16.3%
median 7.6%
Sector rank
#12
of 324 by rating
Valuation vs. quality map
The sweet spot is upper-left: more profitable (higher ROE) for a lower P/E. Dashed lines mark the sector median.
Peers are the closest Health Care companies by sub-industry and size. Sector median is across all 324 S&P 500 names in the sector. Educational, not a recommendation.
Project revenue → earnings → price. Edit the assumptions to build your own case.
2030 price target (Base Case)
$0.00 – $0.00
vs. $230.28 today · expected CAGR 7% – 19%
| Metric | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| Revenue | $3.71B | $4.30B | $4.99B | $5.79B | $6.71B |
| Net income | $1.04B | $1.20B | $1.40B | $1.62B | $1.88B |
| EPS | $7.79 | $9.04 | $10.48 | $12.16 | $14.11 |
| Share price (low) | $179.19 | $207.86 | $241.12 | $279.70 | $324.46 |
| Share price (high) | $303.85 | $352.47 | $408.86 | $474.28 | $550.16 |
| CAGR (low–high) | -22% / 32% | -5% / 24% | 2% / 21% | 5% / 20% | 7% / 19% |
Educational model on sample fundamentals — not a forecast or investment advice. Outputs are only as good as your assumptions.
The case for VEEV:
- Revenue is growing 16.3% a year, a sign of real demand.
- High net margins (28.4%) point to pricing power or efficiency.
- A conservative balance sheet (debt/equity 0.0x) lowers risk.
- Our model's overall read is Favorable (69/100).
The case against VEEV:
- Like any single stock, it is exposed to competition, the economic cycle, and shifts in its end markets.
Valuation risk — at 39.0x earnings, disappointing results could compress the multiple.
Market risk — sector rotation, the economic cycle, and broad sentiment move the stock regardless of fundamentals.
On balance, the fundamentals screen favourably: Veeva Systems is a large-cap health care business still growing nicely, with solid profitability, and a sound balance sheet. It trades at 39.0x earnings, which our model scores Favorable (69/100). Weigh this against your own goals and time horizon — this is educational information, not a recommendation.
Analyst Ratings
What 36 Wall Street analysts covering VEEV recommend (August 2026). Consensus is a useful sanity check — not a substitute for your own homework.
Latest SEC Filings
VEEV's most recent filings, straight from SEC EDGAR. Annual and quarterly reports are the deep dives; 8-Ks flag material events the moment they happen.
In the Idea Lab
VEEV — frequently asked questions
Is VEEV a good stock to buy?
We don't give buy or sell advice. Our model rates Veeva Systems Favorable (69/100) based on its growth, profitability, financial health, and valuation — use that as a research starting point and make your own decision.
What is VEEV's rating on The Stocks School?
Veeva Systems currently scores 69/100 (Favorable) on our transparent model, which weighs real fundamentals: growth, margins, returns on capital, balance-sheet strength, and valuation.
How our ratings work →Where does VEEV's data come from?
Live price data plus real fundamentals and 5-year financials pulled directly from Veeva Systems's SEC filings — refreshed automatically, not hand-entered.
How is the 5-year projection for VEEV calculated?
It's a scenario model: it grows revenue at an assumed rate, applies a profit margin and a valuation multiple, and shows the resulting share-price range. The assumptions are yours to change — it's a tool for thinking, not a prediction.
Is this VEEV analysis financial advice?
No. Everything on this page is educational research, not financial advice or a recommendation to buy or sell VEEV. Always do your own research and consider a licensed professional.
Data notice. Fundamentals and financial statements are sourced from company filings (SEC EDGAR) and market-data providers; prices and market caps refresh on trading days and may be delayed. Ratings, projections, technical signals, and written summaries are model- or rule-generated for education and may simplify or lag the latest filings.
Not advice. Nothing on this page is investment advice or a recommendation to buy, hold, or sell any security. Do your own research and consult a licensed financial professional before investing.